Fresenius Medical Care AG & Co. KGaA / Keyword(s): Personnel
Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet Succeeds Rice Powell as CEO of the Board of Fresenius Medical Care
03-May-2022 / 22:12 CET/CEST
Disclosure of privileged information according to. in Article 17 MAR of Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
At today’s meeting, the Supervisory Board of the General Partner of Fresenius Medical Care unanimously appointed Dr. Carla Kriwet as CEO of the Board of Directors effective January 1, 2023. The Dr Carla Kriwet succeeds Rice Powell, who will leave the Board of Directors in light of the age limit for members of the Management Board when her contract expires at the end of December 2022.
In her capacity as CEO of Fresenius Medical Care, Dr. Carla Kriwet will also be a member of the board of directors of Fresenius Management SE.
Person making the notification:
Dr Dominik Heger
Executive Vice President and Head of Investor Relations, Strategic Development and Communications
+49 6172 609 2601
Fresenius Medical Care is the world’s leading provider of products and services for people with kidney disease, of whom approximately 3.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,171 dialysis clinics, Fresenius Medical Care provides dialysis treatment to approximately 345,000 patients worldwide. Fresenius Medical Care is also the main supplier of dialysis products such as dialysis machines or dialyzers. Along with its core business, the renal care continuum, the Company is focused on expanding into complementary areas and into the area of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).
For more information, visit the company’s website at www.freseniusmedicalcare.com.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to a variety of factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the results of the COVID-19 pandemic from clinical studies, exchange rate fluctuations, uncertainties in legal or investigative proceedings and the availability of funding. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the United States Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA disclaims any responsibility for updating the forward-looking statements contained in this release.
03-May-2022 CET/CEST DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de